Advances in sickle cell disease treatments

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.creatorPavan, Aline Renata [UNESP]-
Autor(es): dc.creatorDos Santos, Jean Leandro [UNESP]-
Data de aceite: dc.date.accessioned2022-02-22T00:47:20Z-
Data de disponibilização: dc.date.available2022-02-22T00:47:20Z-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2020-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.2174/0929867327666200610175400-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/206510-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/206510-
Descrição: dc.descriptionSickle Cell Disease (SCD) is an inherited disorder of red blood cells that is caused by a single mutation in the β-globin gene. The disease, which afflicts millions of patients worldwide mainly in low income countries, is characterized by high morbidity, mortality and low life expectancy. The new pharmacological and non-pharmacological strategies for SCD is urgent in order to promote treatments able to reduce patient’s suffering and improve their quality of life. Since the FDA approval of HU in 1998, there have been few advances in dis-covering new drugs; however, in the last three years voxelotor, crizanlizumab, and glutamine have been approved as new therapeutic alternatives. In addition, new promising compounds have been described to treat the main SCD symptoms. Herein, focusing on drug discovery, we discuss new strategies to treat SCD that have been carried out in the last ten years to discover new, safe, and effective treatments. Moreover, non-pharmacological approaches, including red blood cell exchange, gene therapy and hematopoietic stem cell transplantation will be pre-sented.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-
Descrição: dc.descriptionDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)-
Descrição: dc.descriptionInstitute of Chemistry São Paulo State University (UNESP)-
Descrição: dc.descriptionDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)-
Descrição: dc.descriptionInstitute of Chemistry São Paulo State University (UNESP)-
Descrição: dc.descriptionFAPESP: 2015/19531-1-
Descrição: dc.descriptionFAPESP: 2018/19523-7-
Descrição: dc.descriptionCNPq: 304731/2017-0-
Formato: dc.format2008-2032-
Idioma: dc.languageen-
Relação: dc.relationCurrent Medicinal Chemistry-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectAntisickling-
Palavras-chave: dc.subjectFetal hemoglobin-
Palavras-chave: dc.subjectIron chelation-
Palavras-chave: dc.subjectNew drugs-
Palavras-chave: dc.subjectNitric oxide-
Palavras-chave: dc.subjectRed blood cell-
Palavras-chave: dc.subjectSickle cell disease-
Título: dc.titleAdvances in sickle cell disease treatments-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.